[Skip to Content]
[Skip to Content Landing]

Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis

Educational Objective
To understand that clinical phenotypes of the sepsis syndrome may be associated with different responses to therapies.
1 Credit CME
Key Points

Question  Are clinical sepsis phenotypes identifiable at hospital presentation correlated with the biomarkers of host response and clinical outcomes and relevant for understanding the heterogeneity of treatment effects?

Findings  In this retrospective analysis using data from 63 858 patients in 3 observational cohorts, 4 novel sepsis phenotypes (α, β, γ, and δ) with different demographics, laboratory values, and patterns of organ dysfunction were derived, validated, and shown to correlate with biomarkers and mortality. In the simulations using data from 3 randomized clinical trials involving 4737 patients, the outcomes related to the treatments were sensitive to changes in the distribution of these phenotypes.

Meaning  Four novel clinical phenotypes of sepsis were identified that correlated with host-response patterns and clinical outcomes and may help inform the design and interpretation of clinical trials.

Abstract

Importance  Sepsis is a heterogeneous syndrome. Identification of distinct clinical phenotypes may allow more precise therapy and improve care.

Objective  To derive sepsis phenotypes from clinical data, determine their reproducibility and correlation with host-response biomarkers and clinical outcomes, and assess the potential causal relationship with results from randomized clinical trials (RCTs).

Design, Settings, and Participants  Retrospective analysis of data sets using statistical, machine learning, and simulation tools. Phenotypes were derived among 20 189 total patients (16 552 unique patients) who met Sepsis-3 criteria within 6 hours of hospital presentation at 12 Pennsylvania hospitals (2010-2012) using consensus k means clustering applied to 29 variables. Reproducibility and correlation with biological parameters and clinical outcomes were assessed in a second database (2013-2014; n = 43 086 total patients and n = 31 160 unique patients), in a prospective cohort study of sepsis due to pneumonia (n = 583), and in 3 sepsis RCTs (n = 4737).

Exposures  All clinical and laboratory variables in the electronic health record.

Main Outcomes and Measures  Derived phenotype (α, β, γ, and δ) frequency, host-response biomarkers, 28-day and 365-day mortality, and RCT simulation outputs.

Results  The derivation cohort included 20 189 patients with sepsis (mean age, 64 [SD, 17] years; 10 022 [50%] male; mean maximum 24-hour Sequential Organ Failure Assessment [SOFA] score, 3.9 [SD, 2.4]). The validation cohort included 43 086 patients (mean age, 67 [SD, 17] years; 21 993 [51%] male; mean maximum 24-hour SOFA score, 3.6 [SD, 2.0]). Of the 4 derived phenotypes, the α phenotype was the most common (n = 6625; 33%) and included patients with the lowest administration of a vasopressor; in the β phenotype (n = 5512; 27%), patients were older and had more chronic illness and renal dysfunction; in the γ phenotype (n = 5385; 27%), patients had more inflammation and pulmonary dysfunction; and in the δ phenotype (n = 2667; 13%), patients had more liver dysfunction and septic shock. Phenotype distributions were similar in the validation cohort. There were consistent differences in biomarker patterns by phenotype. In the derivation cohort, cumulative 28-day mortality was 287 deaths of 5691 unique patients (5%) for the α phenotype; 561 of 4420 (13%) for the β phenotype; 1031 of 4318 (24%) for the γ phenotype; and 897 of 2223 (40%) for the δ phenotype. Across all cohorts and trials, 28-day and 365-day mortality were highest among the δ phenotype vs the other 3 phenotypes (P < .001). In simulation models, the proportion of RCTs reporting benefit, harm, or no effect changed considerably (eg, varying the phenotype frequencies within an RCT of early goal-directed therapy changed the results from >33% chance of benefit to >60% chance of harm).

Conclusions and Relevance  In this retrospective analysis of data sets from patients with sepsis, 4 clinical phenotypes were identified that correlated with host-response patterns and clinical outcomes, and simulations suggested these phenotypes may help in understanding heterogeneity of treatment effects. Further research is needed to determine the utility of these phenotypes in clinical care and for informing trial design and interpretation.

Sign in to take quiz and track your certificates

Buy This Activity
Article Information

Corresponding Author: Christopher W. Seymour, MD, MSc, University of Pittsburgh School of Medicine, Keystone Bldg, 3520 Fifth Ave, Ste 100, Pittsburgh, PA 15261 (seymourcw@upmc.edu).

Accepted for Publication: April 24, 2019.

Published Online: May 19, 2019. doi:10.1001/jama.2019.5791

Author Contributions: Dr Seymour had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Seymour, Kennedy, Chang, Clermont, Cooper, Gomez, Opal, van der Poll, Vodovotz, Yealy, Angus.

Acquisition, analysis, or interpretation of data: Seymour, Kennedy, Wang, Chang, Elliott, Xu, Berry, Huang, Kellum, Mi, Talisa, Visweswaran, Vodovotz, Weiss, Yende.

Drafting of the manuscript: Seymour, Kennedy, Wang, Berry, van der Poll, Vodovotz, Yealy, Angus.

Critical revision of the manuscript for important intellectual content: Seymour, Kennedy, Chang, Elliott, Xu, Berry, Clermont, Cooper, Gomez, Huang, Kellum, Mi, Opal, Talisa, Visweswaran, Vodovotz, Weiss, Yende, Angus.

Statistical analysis: Seymour, Kennedy, Wang, Chang, Elliott, Xu, Berry, Mi, Talisa, Weiss, Angus.

Obtained funding: Seymour.

Administrative, technical, or material support: Seymour, Kennedy, van der Poll, Weiss, Yealy, Angus.

Supervision: Seymour, Opal, Vodovotz, Yealy, Angus.

Conflict of Interest Disclosures: Dr Seymour reported receiving personal fees from Edwards Inc and Beckman Coulter Inc. Dr Gomez reported receiving grants from TES Pharma. Dr Huang reported receiving nonfinancial support (procalcitonin assays) from Biomerieux and grants from Thermofisher for microbiome research. Dr Vodovotz reported being the cofounder and a stakeholder in Immunetrics Inc and having a provisional patent application pending. Dr Yende reported receiving personal fees from Atox Bio and grants from Bristol-Myers Squibb. Dr Angus reported receiving personal fees from and serving as a consultant to Ferring Pharmaceuticals, Bristol-Myers Squibb, Bayer AG, and Beckman Coulter Inc; owning stock in Alung Technologies; and having patent applications pending for selepressin (compounds, compositions, and methods for treating sepsis) and proteomic biomarkers of sepsis in elderly patients. No other disclosures were reported.

Funding/Support: Drs Seymour, Gomez, Huang, Kellum, Visweswaran, Vodovotz, and Angus were supported in part by grants R35GM119519, P50GM076659, R34GM102696, R01GM101197, GM107231, R01LM012095, K08GM117310-01A1, and GM61992 from the National Institutes of Health. The GenIMS Study was funded by grant R01 GM61992 from the National Institute of General Medical Sciences with additional support from GlaxoSmithKline for enrollment and clinical data collection.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: Dr Angus is Associate Editor of JAMA, but he was not involved in any of the decisions regarding review of the manuscript or its acceptance.

Meeting Presentation: Presented in part at the international conference of the American Thoracic Society; May 19, 2019; Dallas, Texas.

Additional Contributions: We acknowledge the significant contribution of the patients, families, researchers, clinical staff, and sponsors for the cohort and randomized trial data included in this study. We acknowledge the Biostatistics and Data Management Core at the Clinical Research, Investigation, and Systems Modeling of Acute Illness Center in the Department of Critical Care Medicine at the University of Pittsburgh for preparing the SENECA, GenIMS, ACCESS, ProCESS, and PROWESS trial datasets. We acknowledge Eisai Medical Research Inc for providing the ACCESS trial dataset, and Eli Lilly Inc for providing the PROWESS trial dataset. We acknowledge Gordon Bernard, MD (Vanderbilt University, Nashville, Tennessee) and Anthony C. Gordon, MD (Imperial College, London, England) for their detailed review of the manuscript.

References
1.
Rhee  C, Dantes  R, Epstein  L,  et al.  Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014.  JAMA. 2017;318(13):1241-1249. doi:10.1001/jama.2017.13836PubMedGoogle ScholarCrossref
2.
Seymour  CW, Liu  VX, Iwashyna  TJ,  et al.  Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3).  JAMA. 2016;315(8):762-774. doi:10.1001/jama.2016.0288PubMedGoogle ScholarCrossref
3.
Scicluna  BP, van Vught  LA, Zwinderman  AH,  et al.  Classification of patients with sepsis according to blood genomic endotype.  Lancet Respir Med. 2017;5(10):816-826. doi:10.1016/S2213-2600(17)30294-1PubMedGoogle ScholarCrossref
4.
Sweeney  TE, Azad  TD, Donato  M,  et al.  Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters.  Crit Care Med. 2018;46(6):915-925. doi:10.1097/CCM.0000000000003084PubMedGoogle ScholarCrossref
5.
Davenport  EE, Burnham  KL, Radhakrishnan  J,  et al.  Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study.  Lancet Respir Med. 2016;4(4):259-271. doi:10.1016/S2213-2600(16)00046-1PubMedGoogle ScholarCrossref
6.
Opal  SM, Laterre  PF, Francois  B,  et al; ACCESS Study Group.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis.  JAMA. 2013;309(11):1154-1162. doi:10.1001/jama.2013.2194PubMedGoogle ScholarCrossref
7.
Yealy  DM, Kellum  JA, Huang  DT,  et al; ProCESS Investigators.  A randomized trial of protocol-based care for early septic shock.  N Engl J Med. 2014;370(18):1683-1693. doi:10.1056/NEJMoa1401602PubMedGoogle ScholarCrossref
8.
Bernard  GR, Vincent  JL, Laterre  PF,  et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group.  Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;344(10):699-709. doi:10.1056/NEJM200103083441001PubMedGoogle ScholarCrossref
9.
Kellum  JA, Kong  L, Fink  MP,  et al; GenIMS Investigators.  Understanding the inflammatory cytokine response in pneumonia and sepsis.  Arch Intern Med. 2007;167(15):1655-1663. doi:10.1001/archinte.167.15.1655PubMedGoogle ScholarCrossref
10.
Levy  MM, Fink  MP, Marshall  JC,  et al; SCCM/ESICM/ACCP/ATS/SIS.  2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference.  Crit Care Med. 2003;31(4):1250-1256. doi:10.1097/01.CCM.0000050454.01978.3BPubMedGoogle ScholarCrossref
11.
Vincent  JL, Moreno  R, Takala  J,  et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure.  Intensive Care Med. 1996;22(7):707-710. doi:10.1007/BF01709751PubMedGoogle ScholarCrossref
12.
Medzhitov  R, Schneider  DS, Soares  MP.  Disease tolerance as a defense strategy.  Science. 2012;335(6071):936-941. doi:10.1126/science.1214935PubMedGoogle ScholarCrossref
13.
Angus  DC, Linde-Zwirble  WT, Lidicker  J,  et al.  Epidemiology of severe sepsis in the United States.  Crit Care Med. 2001;29(7):1303-1310. doi:10.1097/00003246-200107000-00002PubMedGoogle ScholarCrossref
14.
Angus  DC, van der Poll  T.  Severe sepsis and septic shock.  N Engl J Med. 2013;369(21):2063.PubMedGoogle Scholar
15.
Newgard  CD, Haukoos  JS.  Advanced statistics: missing data in clinical research—part 2: multiple imputation.  Acad Emerg Med. 2007;14(7):669-678.PubMedGoogle Scholar
16.
Ankerst  M.  OPTICS: ordering points to identify the clustering structure.  SIGMOD Rec. 1999;28(2):49-60. doi:10.1145/304181.304187Google ScholarCrossref
17.
Wilkerson  MD, Hayes  DN.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking.  Bioinformatics. 2010;26(12):1572-1573. doi:10.1093/bioinformatics/btq170PubMedGoogle ScholarCrossref
18.
Calfee  CS, Delucchi  K, Parsons  PE,  et al; NHLBI ARDS Network.  Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials.  Lancet Respir Med. 2014;2(8):611-620. doi:10.1016/S2213-2600(14)70097-9PubMedGoogle ScholarCrossref
19.
Rindskopf  D, Rindskopf  W.  The value of latent class analysis in medical diagnosis.  Stat Med. 1986;5(1):21-27. doi:10.1002/sim.4780050105PubMedGoogle ScholarCrossref
20.
Knaus  WA, Wagner  DP, Draper  EA,  et al.  The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults.  Chest. 1991;100(6):1619-1636. doi:10.1378/chest.100.6.1619PubMedGoogle ScholarCrossref
21.
Deng  M, Scott  MJ, Loughran  P,  et al.  Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4 during sepsis.  J Immunol. 2013;190(10):5152-5160. doi:10.4049/jimmunol.1300496PubMedGoogle ScholarCrossref
22.
Abraham  E, Laterre  PF, Garg  R,  et al; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.  N Engl J Med. 2005;353(13):1332-1341. doi:10.1056/NEJMoa050935PubMedGoogle ScholarCrossref
23.
Ranieri  VM, Thompson  BT, Barie  PS,  et al; PROWESS-SHOCK Study Group.  Drotrecogin alfa (activated) in adults with septic shock.  N Engl J Med. 2012;366(22):2055-2064. doi:10.1056/NEJMoa1202290PubMedGoogle ScholarCrossref
24.
Maitland  K, Kiguli  S, Opoka  RO,  et al; FEAST Trial Group.  Mortality after fluid bolus in African children with severe infection.  N Engl J Med. 2011;364(26):2483-2495. doi:10.1056/NEJMoa1101549PubMedGoogle ScholarCrossref
25.
Andrews  B, Muchemwa  L, Kelly  P, Lakhi  S, Heimburger  DC, Bernard  GR.  Simplified severe sepsis protocol: a randomized controlled trial of modified early goal-directed therapy in Zambia.  Crit Care Med. 2014;42(11):2315-2324. doi:10.1097/CCM.0000000000000541PubMedGoogle ScholarCrossref
26.
Rivers  E, Nguyen  B, Havstad  S,  et al; Early Goal-Directed Therapy Collaborative Group.  Early goal-directed therapy in the treatment of severe sepsis and septic shock.  N Engl J Med. 2001;345(19):1368-1377. doi:10.1056/NEJMoa010307PubMedGoogle ScholarCrossref
27.
Kent  DM, Hayward  RA.  Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification.  JAMA. 2007;298(10):1209-1212. doi:10.1001/jama.298.10.1209PubMedGoogle ScholarCrossref
28.
Berry  SM, Connor  JT, Lewis  RJ.  The platform trial: an efficient strategy for evaluating multiple treatments.  JAMA. 2015;313(16):1619-1620. doi:10.1001/jama.2015.2316PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements